JSSM  Vol.1 No.2 , August 2008
A Preliminary Examination of Risk in the Pharmaceutical Supply Chain (PSC) in the National Health Service (NHS)
Author(s) Liz Breen
ABSTRACT
The effective management of pharmaceuticals in the National Health Service (NHS) is critical to patient welfare thus any risks attached to this must be identified and controlled. At a very basic level, risks in the pharmaceutical supply chain are associated with product discontinuity, product shortages, poor performance, patient safety/dispensing errors, and technological errors (causing stock shortages in pharmacies) to name but a few, all of which incur risk through disruption to the system. Current indications suggest that the pharmaceutical industry and NHS practitioners alike have their concerns as to the use of generic supply chain strategies in association with what is perceived to be a specialist product (pharmaceuticals). The aim of the study undertaken was to gain a more realistic understanding of the nature and prevalence of risk in the Pharmaceutical Supply Chain (PSC) to be used as a basis for a more rigorous research project incorporating in-vestigation in the UK, Europe and USA. Data was collected via a workshop forum held in November 2005. The outputs of the workshop indicated that there were thirty-five prevalent risks. The risks were rated using risk assessment catego-ries such as impact, occurrence and controllability. The findings indicated that the risks identified are similar to those prevalent in industrial supply chains, regardless of the idiosyncrasies of pharmaceuticals. However, the group consen-sus was that caution must be applied in how such risks are addressed, as there are aspects of the product that highlight its uniqueness e.g. criticality.

Cite this paper
nullL. Breen, "A Preliminary Examination of Risk in the Pharmaceutical Supply Chain (PSC) in the National Health Service (NHS)," Journal of Service Science and Management, Vol. 1 No. 2, 2008, pp. 193-199. doi: 10.4236/jssm.2008.12020.
References
[1]   Alldred, A. (2006) Purchasing safer medicines – a na-tional risk assessment strategy. Hospital Pharmacist, January, 3, 17-19.

[2]   Armitage, G., Newell, R. and Wright, J. (2007) Report-ing drug errors in a British acute hospital trust. Clinical Governance: An International Journal, 12 (2), 102-114.

[3]   Blackhurst, J.V., Scheibe, K.P. and Johnson, D.J. (2008) Supplier risk assessment and monitoring for the automotive industry. International Journal of Physical Distribution and Logistics Management, 38 (2), 143-165.

[4]   Chopra, S. and Sodhi, M.S. (2004) Managing risk to avoid supply-chain breakdown. MIT Sloan Manage-ment Review, 46 (1), 53-61.

[5]   Christopher, M, and Lee, H. (2004) Mitigating supply chain risk through improved confidence. International Journal of Physical Distribution and Logistics Man-agement, 34 (5), 388-396.

[6]   Cousins, P., Lamming, R.C. and Bowen, F. (2004) The role of risk in environment-related initiatives. Interna-tional Journal of Operations and Production Manage-ment, 24 (6), 554-565.

[7]   Haigh, J. (2004) IMS Global Consulting, quoted in Parallel Trade in Medicines, Social Market Foundation.

[8]   European Federation of Pharmaceutical Industries and Associations (2005) Pharmaceutical Supply Chain Evolution, EFPIA Position Paper

[9]   Faisal, M.N., Banwet, D.K. and Shankar, R. (2006) Supply chain risk mitigation: modelling the enablers. Business Process Management Journal, 12 (4), 535-552.

[10]   Fraser, I. and Henry, W. (2007) Embedding risk man-agement: structures and approaches. Managerial Audit-ing Journal, 22 (4), 392-409.

[11]   Frosdick, S. (1997) The techniques of risk analysis are insufficient in themselves. Disaster Prevention and Management, 6 (3), 165-177.

[12]   Gaudenzi, B. and Borghesi, A. (2006) Managing risks in the supply chain using the AHP method. The Inter-national Journal of Logistics Management, 17 (1), 114-136.

[13]   Hallikas, J., Karvonen, I., Pulkkinen, U., Virolainen, V.M. and Tuominen, M. (2004) Risk management processes in supplier networks. International Journal of Production Economics, 90, 47-58.

[14]   Harland, C., Brenchley, R. and Walker, H. (2003) Risk in supply networks. Journal of Purchasing and Supply Management, 9, 51-62.

[15]   Hendricks, K.B. and Singhal, V.B. (2005) An empirical analysis of the effects of supply chain disruption on long-run stock price performance and equity risk of the firm. Production and Operations Management, 14 (1), 35-52.

[16]   Khan, O., Burnes, B. and Christopher, M. (2007) Risk and supply chain management: creating a research agenda. The International Journal of Logistics Man-agement, 18 (2), 197-216.

[17]   Knight, L.K. (2005) Roles, Relationships and Dynam-ics of the Pharma Network. A discussion document on opportunities for supply research, Draft internal report to the NHS Purchasing and Supply Agency 2005.

[18]   Manuj, I and Mentzer, J.T. (2008) Global supply chain risk management strategies. International Journal of Physical Distribution and Logistics Management, 38 (3), 192-223.

[19]   Matthew, L. and Bain, T. (2006) Bridging the Gap. Patient Safety: the role of the National Patient Safety Agency (NPSA) in helping pharmacists to improve pa-tient safety. Pharmacy Management, 22 (3), 2-8.

[20]   Papadakis, I. (2006) Financial performance or supply chains after disruptions: an event study. Supply Chain Management: An International Journal, 11 (1), 25-33.

[21]   Pharma Anti-Counterfeiting News (2008) Launch of a New European Safe Medicines Group, (3), 1-4.

[22]   Peck, H. (2005), Drivers of supply chain vulnerability: an integrated framework. International Journal of Physical Distribution and Logistics Management, 35 (4), 210-232.

[23]   Ritchie, B. and Brindley, C. (2007) Supply chain risk management and performance. A guiding framework for future development. International Journal of Operations and Production Management, 27 (3), 303-322.

[24]   Savage, C.J., Roberts, K.J., and Wang, X.Z. (2006) A holistic analysis of pharmaceutical manufacturing and distribution: are conventional supply chain techniques appropriate? Pharmaceutical Engineering July/August, 10-18.

[25]   Smallman, C. (1999a) Knowledge management as Risk management: A Need for Open Governance? Risk Management, an International Journal, 1 (4), 7-20.

[26]   Smallman, C. (1999b) The Risk Factor Financial Times Mastering Management Review, 30, 42-45, December.

[27]   Smallman, C. (1996) Risk and organisational behaviour: a research model. Disaster Prevention and Management, 5 (2), 12-26.

[28]   Tang, C. and Tomlin, B. (2008) The power of flexibil-ity for mitigating supply chain risks. International Journal of Production Economics, doi:10.1016/j.ijpe.2008.07.008

[29]   Wills, S. and Stephens, M. (2007) How safe is informa-tion about medicines? A risk assessment framework. Clinical Governance: An International Journal, 12 (1), 2-37.

[30]   World Health Organisation (2006) Counterfeit medi-cines. Accessed: 12/1/07.

[31]   http://www.who.int/mediacentre/factsheets/fs275/es/

[32]   Zsidisin, G., Melnyk, S.A., Ragatz, G.L. and Burns, L.A. (2006) Preliminary findings from a supply risk audit instrument. Proceedings to IPSERA Conference, Paper 43.

 
 
Top